๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Ocugen, Inc. (OCGN)
NASDAQ: OCGN ยท Real-Time Price ยท USD
0.7392
-0.0175 (-2.31%)
At close: Nov 18, 2026, 4:00 PM EST
0.7490
+0.0098 (1.33%)
After-hours: Nov 18, 2026, 7:56 PM EST

Ocugen Earnings Call Transcripts

Fiscal Year 2026

  • Late-stage retinal gene therapy programs have 2027 readouts ahead, led by OCU400 Phase III topline expected in Q1. Plans include a Q2 BLA filing, expanded treatment centers, and funding runway into 2028.

  • All three late-stage gene therapy programs are in Phase III, with OCU400 top-line data expected in Q1 2027 and three BLAs targeted by 2028. Cash and investments of $84.6M are expected to support runway into 2028.

  • EGM 2026

    The charter amendment to add 250 million authorized common shares lacked sufficient proxy support, so polls were not opened and the item was adjourned to October 26, 2026. The adjournment proposal had already passed; prior proxy votes remain valid unless revoked.

  • EGM 2026

    The meeting focused on increasing authorized shares and adjournment to solicit more proxies. The share increase proposal did not receive sufficient approval, so the meeting was adjourned to allow further voting, with the next session scheduled for October 5, 2026.

  • Three late-stage gene therapy programs are advancing toward BLA submissions through 2028, with strong regulatory support and a focus on one-time treatments for major retinal diseases. Operational and commercialization plans prioritize U.S. launch, strategic partnerships abroad, and careful capital management to extend runway into 2028.

  • Late-stage gene therapy programs for blindness diseases are advancing, with pivotal data for RP and Stargardt expected in 2024 and potential global launches by 2028. The platform targets broad disease pathways, has strong safety data, and is supported by RMAT designation and extended financial runway.

  • FDA cleared phase III for OCU410 in GA and granted RMAT designation; $130M financing extends cash runway into 2028. Three late-stage programs advance toward BLA filings by 2028, with top-line data for OCU400 and OCU410ST expected in H1 2027.

  • Three late-stage gene therapy programs are advancing for retinitis pigmentosa, Stargardt disease, and geographic atrophy, with two BLAs planned next year and a third in 2028. Phase II/III data show strong efficacy and safety, and adaptive trial designs aim to optimize outcomes.

  • AGM 2026

    The meeting, held virtually for accessibility, included director elections, ratification of the accounting firm, and advisory votes on executive compensation and its voting frequency. All proposals passed, and a brief Q&A followed with no further questions.

  • Gene therapy programs for retinal diseases show strong efficacy, with OCU410 reducing GA lesion growth by 31% in one year and OCU400 targeting RP across 100+ mutations. Three pivotal trials are advancing globally, with major regulatory filings and potential approvals expected by 2028.

  • Three late-stage gene therapy programs are advancing for major retinal diseases, using master regulator genes to address broad patient populations and unmet needs. Rolling BLA submissions and adaptive trial designs aim for regulatory filings by 2028, supported by strong cash reserves and global market strategy.

  • Q1 2026 saw major clinical and financial milestones, including a $115M convertible notes offering, positive phase II data in GA, and completed pivotal trial enrollments. Cash runway is projected into 2028, supporting three BLA submissions by 2028.

  • Study update

    The phase II ArMaDa trial of OCU410 in GA showed a 31% reduction in lesion growth and 27% slower ellipsoid zone loss at 12 months, with a favorable safety profile and no treatment-related serious adverse events. Medium dose was optimal, supporting advancement to a global phase III trial.

  • Study result

    OCU410, a one-time gene therapy for geographic atrophy, showed a 46% reduction in lesion growth at 12 months in phase II, with a strong safety profile and up to 50% of patients achieving significant benefit. The therapy targets multiple disease pathways and may offer a durable alternative to chronic injections.

Fiscal Year 2025

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021

Fiscal Year 2020